European Journal of Clinical Pharmacology

, Volume 45, Issue 6, pp 495–501 | Cite as

Use of psychotropic drugs during pregnancy

A report of the international co-operative drug use in pregnancy (DUP) study
  • F. Marchetti
  • M. Romero
  • M. Bonati
  • G. Tognoni
  • Collaborative Group on Drug Use in Pregnancy (CGDUP)


Drug Use in Pregnancy (DUP) is an international epidemiological survey of drug use in pregnancy conducted from 1988 to 1990 in 148 maternity wards, representing the general delivery practices of 22 countries. Data on exposure of pregnant women to psychotropic drugs, the indications for their use and their correlation with maternal characteristics are reported.

Of the 14,778 women interviewed, 520 (3.5%) reported 562 courses of psychotropic drugs. Benzodiazepines (BDZ) accounted for the greatest number of the exposures (444/520 women); neuroleptics and antidepressants were prescribed to tiny minorities of women (83 and 17 respectively), mostly in those few countries were the overall prevalence of use of those drugs was highest. Throughout the majority of the other countries, overall rates were in the low range and were rather heterogeneous. With the exception of small clusters of “unexpected” indications, prescriptions of BDZ were found to be consistent with the target symptoms of anxiety and insomnia; chronic use was reported in 31/444 women. The study was not targeted to the detection of malformations; no suspected clustering was found, however, among the 130 women exposed during the first trimester of pregnancy.

The collaborative network now established provides a framework for periodically replicated surveillance to monitor the evolution of this field of knowledge and care in order to provide reliable information for women and society.

Key words

Pregnancy methodological Psychotropic drugs drug utilisation 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bonati M, Bortolus R, Marchetti F, Romero M, Tognoni G (1990) Drug use in pregnancy: an overview of epidemiological (drug utilization) studies. Eur J Clin Pharmacol 38: 325–328Google Scholar
  2. 2.
    Chalmers I, Enkin M, Keirse MJ (ed) (1989) Effective care in pregnancy and childbirth. Oxford University Press, OxfordGoogle Scholar
  3. 3.
    Medawar C (1992) Poxer and dependence. Social audit on the safety of medicines. Social Audit. LondonGoogle Scholar
  4. 4.
    Oswald I (1989) Triazolam syndrome 10 years on. Lancet II: 451–452Google Scholar
  5. 5.
    Lenz W (1984) Lessons to be learned from thalidomide. In: Drugs in pregnancy and delivery. Report on the Thirteenth European Symposium on Clinical Pharmacological Evaluation in Drug Control. WHO Regional Office for Europe, Copenhagen, pp 45–51Google Scholar
  6. 6.
    Farrar HC, Blumer JL (1991) Fetal effects of maternal drug exposure. Annu Rev Pharmacol Toxicol 31: 525–547Google Scholar
  7. 7.
    Heinonen OP, Slone D, Shapiro S (1977) Birth defects and drugs in pregnancy. Publishing Sciences Group, LittletonGoogle Scholar
  8. 8.
    Nora JJ, Nora AII, Sommerville RJ, Hill RM, McNamara DG (1967) Maternal exposure to potential teratogens. JAMA 202: 91–95Google Scholar
  9. 9.
    Forfar JO, Nelson MM (1973) Epidemiology of drugs taken by pregnant women: drugs that may affect the fetus adversely. Clin Pharmacol Ther 14: 632–642Google Scholar
  10. 10.
    Kullander S, Källén B (1976) A prospective study of drugs and pregnancy. Acta Obstet Gynecol Scand 55: 25–33Google Scholar
  11. 11.
    Hill RM (1973) Drugs ingested by pregnant women. Clin Pharmacol Ther 14: 654–659Google Scholar
  12. 12.
    Boethius G (1977) Recording of drug prescriptions in the Country of Jämtland, Sweden. II. Drug exposure of pregnant women in relation to course and outcome of pregnancy. Eur J Clin Pharmacol 12: 37–43Google Scholar
  13. 13.
    Doering PL, Stewart RB (1978) The extent and character of drug consumption during pregnancy. JAMA 239: 843–846Google Scholar
  14. 14.
    Johnson FL, Winship III HW, Trinca CE (1977) Neonatal medication surveillance by the pharmacist. Am J Hosp Pharm 34: 609–612Google Scholar
  15. 15.
    Brocklebank JC, Ray WA, Federspiel CF, Schaffner W (1978) Drug prescribing during pregnancy. A controlled study of Tennessee medicaid recipients. Am J Obstet Gynecol 132: 235–244Google Scholar
  16. 16.
    Buitendijk S, Bracken MB (1991) Medication in early pregnancy: prevalence of use and relationship to maternal characteristics. Am J Obstet Gynecol 165: 33–40Google Scholar
  17. 17.
    Rubin PC, Craig GF, Gavin K, Sumner D (1986) Prospective survey of use of therapeutic drugs, alcohol, and cigarettes during pregnancy. BMJ 292: 81–83Google Scholar
  18. 18.
    Collaborative Group on Drug Use in Pregnancy (1990) Drug use in pregnancy: a preliminary report of the International Co-operative Drug Utilization Study. Pharm Weekbl (Sci) 12: 75–78Google Scholar
  19. 19.
    Collaborative Group on Drug Use in Pregnancy (CGDUP) (1991) An international survey on drug utilization during pregnancy. Int J Safety Risk Medicine 2: 1–5Google Scholar
  20. 20.
    Collaborative Group on Drug Use in Pregnancy (CGDUP) (1992) Medication during pregnancy: an intercontinental co-operative study. Int J Gynecol Obstet 39: 185–196Google Scholar
  21. 21.
    Harlow SD, Linet MS (1989) Agreement between questionnaire data and medical records: the evidence for accuracy of recall. Am J Epidemiol 129: 233–248Google Scholar
  22. 22.
    Reynolds JEF (ed) (1989) Martindale: the extra pharmacopoeia, 29th edn. The Pharmaceutical Press, LondonGoogle Scholar
  23. 23.
    De Jong-van den Berg L (1992) Drug utilization studies in pregnancy: what can they contribute to safety assessment (doctoral thesis) STYX, GroningenGoogle Scholar
  24. 24.
    Safra MJ, Oakley GP (1975) Association between cleft lip with or without cleft palate and prenatal exposure to diazepam. Lancet II: 478–480Google Scholar
  25. 25.
    Rosenberg L, Mitchell AA, Parsells JL, Pashayan H, Louik C, Shapiro S (1983) Lack of relation of oral clefts to diazepam use during pregnancy. N Engl J Med 309: 1282–1285Google Scholar
  26. 26.
    Laegreid L, Olegard R, Wahlström J, Conradi N (1987) Abnormalities in children exposed to benzodiazepines in utero. Lancet I: 108–109Google Scholar
  27. 27.
    Laegreid L, Olegard R, Walström J, Conradi N (1989) Teratogenic effects of benzodiazepine use during pregnancy. J Pediatr 114: 126–131Google Scholar
  28. 28.
    Laegreid L (1990) Clinical observations in children after prenatal benzodiazepine exposure. Dev Pharmacol Ther 15: 186–188Google Scholar
  29. 29.
    Barry WS, St Clair SM (1987) Exposure to benzodiazepines in utero. Lancet I: 1436–1437Google Scholar
  30. 30.
    Bergman U, Boethius G, Swartling PG, Isacson D, Smedby B (1990) Teratogenic effects of benzodiazepine use during pregnancy. J Pediatr 116: 490–491Google Scholar
  31. 31.
    Bergman U (1991) Pharmacoepidemiological perspectives on the suspected teratogenic effects of benzodiazepines. Bratisl Lek Listy 92: 560–563Google Scholar
  32. 32.
    Bergman U, Rosa FW, Baum C, Wiholm B-E, Faich GA (1992) Effects of exposure to benzodiazepine during fetal life. Lancet 340: 694–696Google Scholar
  33. 33.
    Laegreid L, Hagberg G, Lundberg A (1992) The effect of benzodiazepines on the fetus and the newborn. Neuropediatrics 23: 18–23Google Scholar
  34. 34.
    St Clair SM, Schirmer RG (1992) First-trimester exposure to alprazolam. Obstet Gynecol 80: 843–846Google Scholar
  35. 35.
    Woods JH, Katz JL, Winger G (1988) Use and abuse of benzodiazepines. Issues relevant to prescribing. JAMA 260: 3476–3480Google Scholar
  36. 36.
    Tyrer P (1989) Risks of dependence on benzodiazepine drugs: the importance of patient selection. BMJ 298: 102–105Google Scholar
  37. 37.
    Ashton H (1989) Risks of dependence on benzodiazepine drugs: a major problem of long term treatment. BMJ 298: 103–104Google Scholar
  38. 38.
    Dukes MNG (ed) (1993) Drug utilization studies. Methods and uses. World Health Organization Regional Office for Europe, CopenhagenGoogle Scholar
  39. 39.
    Kasilo O, Romero M, Bonati M, Tognoni G (1988) Information on drug use in pregnancy from the viewpoint Regional Drug Information Centre. Eur J Clin Pharmacol 35: 447–453Google Scholar

Copyright information

© Springer-Verlag 1993

Authors and Affiliations

  • F. Marchetti
    • 1
  • M. Romero
    • 1
  • M. Bonati
    • 2
  • G. Tognoni
    • 1
  • Collaborative Group on Drug Use in Pregnancy (CGDUP)
  1. 1.Laboratory of Clinical Pharmacology and EpidemiologyConsorzio Mario Negri Sud, S. Maria ImbaroChietiItaly
  2. 2.Laboratory for Mother and Child HealthIstituto di Ricerche Farmacologiche “Mario Negri”MilanoItaly

Personalised recommendations